TAK-102

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug NameTAK-102

Drug Alias NameTAK-102NIB-102

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsGlypican-3 inhibitors +[6]

TargetsGlypican-3Interleukin-7 receptorsC-C chemokine receptor type 7

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNoile-Immune Biotech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTakeda Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A